The content of the proposed panel for CSF +/− LM (lymphoma) is PTPRC, SERPINC1, sCD44, sCD14, ANPEP, SPP1, FCGR1A, C9, sCD34, sCD19, CCND2, C1QB, NCAM1, TP53, PIM1; which displayed AUC 76.3% with a sensitivity of >81% and specificity of >62% for the protein arrays; meanwhile, AUC was >81% with a sensitivity of >71% and specificity of >73% by affinity proteomics (Figure 8a, Table S8), whereas the proposed panel for CSF + LM (leukemia) was AUC > 78% for protein arrays and >84% by affinity proteomics (Figure 8b, Table S8). This evidence concerns the gene CCND2 and leukemia.